FHTX

insider transactions

Foghorn Therapeutics Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Other·G
Apr 10, 26

Adrian Gottschalk KEY

Chief Executive Officer

$0

59.2K sh

Own -20%
Other·G
Apr 9, 26

Adrian Gottschalk KEY

Chief Executive Officer

$0

47.5K sh

Own -100%
Grant·A
Feb 23, 26

Ryan D Maynard KEY

Chief Financial Officer

$2.3M

400.0K sh · $5.75

Own New
Grant·A
Feb 5, 26

Adrian Gottschalk KEY

Chief Executive Officer

$5.6M

1.1M sh · $5.23

Own New
Grant·A
Jan 30, 26

Anna Rivkin

Chief Business Officer

$942.1K

165.0K sh · $5.71

Own New
Grant·A
Jan 30, 26

Michael Lacascia

Chief Legal Officer

$1.7M

295.0K sh · $5.71

Own New
Grant·A
Jan 30, 26

Carlos Costa

Chief People Officer

$1.3M

230.0K sh · $5.71

Own New
Grant·A
Jan 30, 26

Alfonso Quintas Cardama

Chief Medical Officer

$1.7M

300.0K sh · $5.71

Own New
Grant·A
Jan 30, 26

Steven F. Bellon

Chief Scientific Officer

$1.7M

300.0K sh · $5.71

Own New

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Apr 10, 2026	Adrian Gottschalk KEY	Chief Executive Officer	Other G	59.2K	-20%	—	$0
Apr 9, 2026	Adrian Gottschalk KEY	Chief Executive Officer	Other G	47.5K	-100%	—	$0
Feb 23, 2026	Ryan D Maynard KEY	Chief Financial Officer	Grant A	400.0K	New	$5.75	$2.3M
Feb 5, 2026	Adrian Gottschalk KEY	Chief Executive Officer	Grant A	1.1M	New	$5.23	$5.6M
Jan 30, 2026	Anna Rivkin	Chief Business Officer	Grant A	165.0K	New	$5.71	$942.1K
Jan 30, 2026	Michael Lacascia	Chief Legal Officer	Grant A	295.0K	New	$5.71	$1.7M
Jan 30, 2026	Carlos Costa	Chief People Officer	Grant A	230.0K	New	$5.71	$1.3M
Jan 30, 2026	Alfonso Quintas Cardama	Chief Medical Officer	Grant A	300.0K	New	$5.71	$1.7M
Jan 30, 2026	Steven F. Bellon	Chief Scientific Officer	Grant A	300.0K	New	$5.71	$1.7M

About FHTX insider trading

This page tracks insider transactions for Foghorn Therapeutics Inc. (FHTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.